When STAT’s Adam Feuerstein named Tim Van Hauwermeiren to his list of the best CEOs of 2023, he called him a “low-key leader” who’s built a biotech company with a $30 billion market cap with little fanfare and a lot of clinical and commercial success. Argenx’s antibody drug Vyvgart, which treats an autoimmune disease called myasthenia gravis, brought in $1.2 billion in revenue in 2023. And in 2023, the company also ran a successful Phase 3 trial showing the drug’s efficacy in slowing the progression of a different immune disorder, chronic inflammatory demyelinating polyneuropathy — one of a dozen conditions for which Vyvgart is currently being studied as a potential treatment.
Industry
Location
-
Ghent, Belgium
